Lung scarring claims 11 Aussie lives a day: report

6 minute read


A landmark Australian report has revealed the growing burden of pulmonary fibrosis, with one in five cases linked to occupational exposures.


Respiratory experts have called for an overhaul of Australia’s approach to pulmonary fibrosis, with new modelling revealing the incurable lung condition claims almost 4000 lives a year and imposes an annual economic and societal burden of $4.2 billion.

The Burden of Pulmonary Fibrosis: Hard Truths of Lung Scarring in Australia report estimated 21,995 Australians were living with pulmonary fibrosis in 2025, a 34% increase since 2016.

Of those, 13,391 had idiopathic pulmonary fibrosis (IPF) and 8604 had progressive pulmonary fibrosis (PPF), the report revealed.

By 2030, annual new diagnoses are projected to reach 8821, prevalence to exceed 25,000 and annual deaths to surpass 4500, with the economic burden approaching $4.9 billion.

More than 20,000 Australians living with pulmonary fibrosis are projected to die between 2026 and 2030.

The report estimated 21% of pulmonary fibrosis cases could be prevented by eliminating occupational exposures, highlighting the risks associated with hazardous dusts, vapours, and chemicals across industries including mining, agriculture, construction, manufacturing, dentistry, and hairdressing.

An estimated 827 Australians died from exposure-related pulmonary fibrosis in 2025, with annual deaths projected to approach 1000 by 2030.

Report contributor and University of Queensland respiratory physician Professor Dan Chambers said Australia’s response to silicosis provided a foundation for addressing the broader burden of pulmonary fibrosis.

“While the banning of silica in engineered stone and a national registry for dust diseases is a strong start, more action is needed to reduce the risk of exposure-related lung scarring,” he said.

“Despite claiming the lives of thousands of Australians, lung scarring is under recognised and under resourced with significant gaps in prevention, detection and treatment.”

The report identified diagnostic delays as a significant barrier to improving patient outcomes, with more than half of patients reporting a previous misdiagnosis.

Published research identified delays of between seven months and more than five years from symptom onset to an accurate diagnosis, while members of the report’s advisory group said the diagnostic journey could take as long as a decade.

Early symptoms, including persistent cough, breathlessness and fatigue, were often attributed to more common respiratory conditions, ageing, or declining physical fitness.

Centre of Research Excellence in Pulmonary Fibrosis’s Professor Tamera Corte said diagnostic delays were robbing patients of opportunities for therapeutic intervention.

“Most patients are diagnosed with another heart or lung condition in the 10 years before their PF diagnosis, meaning that the diagnosis of PF is often delayed,” she said in the report.

“This delay in diagnosis, means that patients miss out on treatments which can stabilise or slow the progression of their disease. This can have major impact on both their quality of life and survival.”

The report recommended developing accredited education modules and clinical decision-support tools for GPs, alongside clearer referral pathways and guidance on when to request high-resolution CT imaging.

It also called for reform of funding arrangements for multidisciplinary meetings (MDMs), which play a critical role in establishing a pulmonary fibrosis diagnosis and facilitating access to PBS-subsidised antifibrotic therapies.

More than half of referred cases had their diagnosis changed following multidisciplinary review, according to research cited in the report.

However, existing funding arrangements did not reflect contemporary models of multidisciplinary care and could restrict access to specialist review, particularly for patients outside metropolitan centres.

The authors called for nationally consistent funding arrangements and greater support for virtual and hub-and-spoke models of multidisciplinary assessment.

Public funding for genetic testing and counselling, alongside a national pulmonary fibrosis genetic services framework, was another priority, particularly for patients with early-onset disease or a family history of interstitial lung disease.

Lung Foundation Australia CEO Mark Brooke renewed calls for the federal government to expand the National Lung Cancer Screening Program into an integrated, multi-disease lung screening initiative.

Previous research suggests 8-10% of people undergoing lung cancer screening have interstitial lung abnormalities that could indicate early fibrosis, presenting an opportunity for further investigation.

“This report must act as a wake-up call to improve prevention, as well as bolster detection and treatment of this terminal illness,” Mr Brooke said.

Geographical disparities in access to care were also highlighted in the report, with approximately 21% of Australians living with pulmonary fibrosis residing in regional and rural areas.

Heart of Australia founder Dr Rolf Gomes said mobile screening services were uncovering evidence of lung scarring in communities with high levels of occupational exposure.

“The more lungs we examine, the more people we find with signs of lung scarring, especially in farming and mining communities where exposure to hazardous dusts, vapours and chemicals can be high,” he said.

“We know that many Australians with lung scarring wait years for a diagnosis and face delays in accessing specialist care, particularly in regional areas.”

The report’s economic modelling estimated direct healthcare costs associated with pulmonary fibrosis reached $713 million in 2025, with governments bearing almost 97% of those costs.

Acute medical care, including hospitalisations and emergency department presentations, accounted for $300 million, followed by non-acute medical care ($237.5 million), and end-of-life care ($106.6 million).

By comparison, expenditure on antifibrotic therapies accounted for just 5.5% of direct healthcare costs, at $39 million.

Productivity losses and the impact on carers contributed a further $163 million in indirect costs, while the estimated value of lost wellbeing associated with diminished quality of life and premature mortality exceeded $3.3 billion.

The researchers said that the overall burden was likely to be underestimated, with the modelling unable to fully capture early retirement, reductions in working hours, travel for specialist care and the emotional toll on patients and their families.

While nintedanib and pirfenidone are available through the PBS for eligible patients with IPF, and nintedanib for eligible patients with PPF, treatment options remain limited for those unable to tolerate existing therapies or whose disease progresses despite treatment.

“Clearly, more needs to be done to limit exposure to hazardous dusts, improve early and accurate diagnosis and end a ten-year new treatment drought for the growing number of Australians with irreversibly scarred lungs,” Professor Chambers said.

The report called for increased investment in pulmonary fibrosis research, improved reimbursement processes for innovative medicines and equitable access to multidisciplinary care, including pulmonary rehabilitation, oxygen therapy, and supportive care.

The researchers said that Australia’s coordinated national responses to lung cancer and silicosis demonstrated what could be achieved through targeted investment, regulatory reform and greater clinical awareness.

“Australia can no longer afford to overlook pulmonary fibrosis,” they wrote.

“Pulmonary fibrosis deserves the same level of recognition and commitment.”

The report was commissioned by Boehringer Ingelheim Australia and developed by HTAnalysts with support from Lung Foundation Australia, the Centre of Research Excellence in Pulmonary Fibrosis, and Heart of Australia.

Read the full report here.

End of content

No more pages to load

Log In Register ×